Comparing Natus Medical (NASDAQ:BABY) and Second Sight Medical Products (NASDAQ:EYES)

Share on StockTwits

Natus Medical (NASDAQ:BABY) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Natus Medical and Second Sight Medical Products’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Natus Medical $530.89 million 2.04 -$22.93 million $1.42 22.48
Second Sight Medical Products $6.90 million 14.04 -$35.09 million ($0.52) -1.50

Natus Medical has higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Natus Medical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Natus Medical and Second Sight Medical Products, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natus Medical 0 1 1 0 2.50
Second Sight Medical Products 0 0 1 0 3.00

Natus Medical presently has a consensus price target of $36.00, suggesting a potential upside of 12.78%. Second Sight Medical Products has a consensus price target of $5.00, suggesting a potential upside of 541.11%. Given Second Sight Medical Products’ stronger consensus rating and higher possible upside, analysts plainly believe Second Sight Medical Products is more favorable than Natus Medical.

Profitability

This table compares Natus Medical and Second Sight Medical Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Natus Medical -7.38% 10.79% 6.57%
Second Sight Medical Products -553.01% -248.94% -153.13%

Insider and Institutional Ownership

91.6% of Natus Medical shares are held by institutional investors. Comparatively, 6.1% of Second Sight Medical Products shares are held by institutional investors. 1.7% of Natus Medical shares are held by insiders. Comparatively, 76.2% of Second Sight Medical Products shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Natus Medical beats Second Sight Medical Products on 8 of the 13 factors compared between the two stocks.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. Additionally, it offers jaundice management products; brain injury products; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Pleasanton, California.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.